-
A Parallel-Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
If you have been diagnosed with advanced prostate cancer with high levels of DickkopM (DKK1), you may qualify for this Phase 1b/2a study investigating ... -
Sangamo Fabry disease gene therapy study (ST-920-201)
Fabry disease is caused by mutations in the GLA gene. The GLA gene encodes the lysosomal enzyme alpha-galactosidase A, or a-Gal A for short. When ... -
A Phase 1b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer
The purpose of the study is to determine the safety and efficacy of the treatments: AB928, a novel adenosine receptor blocker, plus zimberelimab, an anti-PD1 ...